Literature DB >> 16827620

CpG oligonucleotides accelerate and boost the immune response elicited by AVA, the licensed anthrax vaccine.

Dennis M Klinman1.   

Abstract

Synthetic oligodeoxynucleotides (ODN) containing unmethylated CpG motifs act as immune adjuvants, improving the immune response elicited by coadministered vaccines. Combining CpG ODN with anthrax vaccine adsorbed (AVA), the licensed human vaccine, can increase the speed, magnitude and avidity of the resultant anti-anthrax response in mice, rhesus macaques and humans. Adsorbing the CpG ODN onto cationic poly(actide-coglycolides) microparticles further boosts immunity to coadministered AVA. The antibody response induced by CpG ODN plus AVA confers protection against systemic anthrax challenge in multiple animal models. These findings suggest that CpG ODN, alone or in combination with other adjuvants and delivery strategies, may support the development of prophylactic and therapeutic vaccines against biothreat pathogens.

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16827620     DOI： 10.1586/14760584.5.3.365

Source DB:  PubMed          Journal:  Expert Rev Vaccines        ISSN： 1476-0584            Impact factor:   5.217


  9 in total

1.  Correlation between anthrax lethal toxin neutralizing antibody levels and survival in guinea pigs and nonhuman primates vaccinated with the AV7909 anthrax vaccine candidate.

Authors:  Vladimir Savransky; Jeffry D Shearer; Melicia R Gainey; Daniel C Sanford; Gloria S Sivko; Gregory V Stark; Na Li; Boris Ionin; Michael J Lacy; Mario H Skiadopoulos
Journal:  Vaccine       Date:  2017-07-31       Impact factor: 3.641

2.  Assessing the immunopotency of Toll-like receptor agonists in an in vitro tissue-engineered immunological model.

Authors:  Yifan Ma; Louis Poisson; Guzman Sanchez-Schmitz; Santosh Pawar; Chunfeng Qu; Gwendalyn J Randolph; William L Warren; Eric M Mishkin; Russell G Higbee
Journal:  Immunology       Date:  2010-03-17       Impact factor: 7.397

Review 3.  Targeting the TLR9-MyD88 pathway in the regulation of adaptive immune responses.

Authors:  Xiaopei Huang; Yiping Yang
Journal:  Expert Opin Ther Targets       Date:  2010-08       Impact factor: 6.902

4.  An intranasally delivered Toll-like receptor 7 agonist elicits robust systemic and mucosal responses to Norwalk virus-like particles.

Authors:  Lissette S Velasquez; Brooke E Hjelm; Charles J Arntzen; Melissa M Herbst-Kralovetz
Journal:  Clin Vaccine Immunol       Date:  2010-10-20

5.  In vivo efficacy of a phosphodiester TLR-9 aptamer and its beneficial effect in a pulmonary anthrax infection model.

Authors:  Christina C N Wu; Mojgan Sabet; Tomoko Hayashi; Rommel Tawatao; Joshua Fierer; Dennis A Carson; Donald G Guiney; Maripat Corr
Journal:  Cell Immunol       Date:  2008-05-20       Impact factor: 4.868

6.  Evaluation of the AV7909 Anthrax Vaccine Toxicity in Sprague Dawley Rats Following Three Intramuscular Administrations.

Authors:  Veena V Rao; C Steven Godin; Michael J Lacy; Jon R Inglefield; Sukjoon Park; Bruna Blauth; Joshua J Reece; Boris Ionin; Vladimir Savransky
Journal:  Int J Toxicol       Date:  2021-07-19       Impact factor: 2.032

7.  CpG increases vaccine antigen-specific cell-mediated immunity when administered with hepatitis B vaccine in HIV infection.

Authors:  Jonathan B Angel; Curtis L Cooper; Jennifer Clinch; Charlene D Young; Andreane Chenier; Karl G Parato; Michael Lautru; Heather Davis; Donald W Cameron
Journal:  J Immune Based Ther Vaccines       Date:  2008-08-12

8.  Phase 1 trial of AMA1-C1/Alhydrogel plus CPG 7909: an asexual blood-stage vaccine for Plasmodium falciparum malaria.

Authors:  Gregory E D Mullen; Ruth D Ellis; Kazutoyo Miura; Elissa Malkin; Caroline Nolan; Mhorag Hay; Michael P Fay; Allan Saul; Daming Zhu; Kelly Rausch; Samuel Moretz; Hong Zhou; Carole A Long; Louis H Miller; John Treanor
Journal:  PLoS One       Date:  2008-08-13       Impact factor: 3.240

Review 9.  Preparation of recombinant vaccines.

Authors:  Eric Soler; Louis-Marie Houdebine
Journal:  Biotechnol Annu Rev       Date:  2007
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.